Journal
NATURE
Volume 461, Issue 7268, Pages 1287-U125Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nature08541
Keywords
-
Categories
Funding
- National Institutes of Health [GM-38765, P50-DE016191]
- Welcome Trust [086867/Z/08/Z, 085903/Z/08]
- Arthritis Research Campaign UK [18445, 18103]
- NHLBI [HL087526]
- Wellcome Trust [086867/Z/08/Z] Funding Source: Wellcome Trust
- Versus Arthritis [18103] Funding Source: researchfish
Ask authors/readers for more resources
A growing body of evidence indicates that resolution of acute inflammation is an active process(1,2). Resolvins are a new family of lipid mediators enzymatically generated within resolution networks that possess unique and specific functions to orchestrate catabasis, the phase in which disease declines(2,3). Resolvin D2 (RvD2) was originally identified in resolving exudates, yet its individual contribution in resolution remained to be elucidated. Here, we establish RvD2's potent stereoselective actions in reducing excessive neutrophil trafficking to inflammatory loci. RvD2 decreased leukocyte-endothelial interactions in vivo by endothelial-dependent nitric oxide production, and by direct modulation of leukocyte adhesion receptor expression. In mice with microbial sepsis initiated by caecal ligation and puncture, RvD2 sharply decreased both local and systemic bacterial burden, excessive cytokine production and neutrophil recruitment, while increasing peritoneal mononuclear cells and macrophage phagocytosis. These multi-level pro-resolving actions of RvD2 translate to increased survival from sepsis induced by caecal ligation and puncture and surgery. Together, these results identify RvD2 as a potent endogenous regulator of excessive inflammatory responses that acts via multiple cellular targets to stimulate resolution and preserve immune vigilance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available